Genetic analysis made easy | BioStrandTime 2022-10-10 07:26:22
Web Name: Genetic analysis made easy | BioStrand
ONE Solution For All Multi-OMICs Data Analysis & Management
Accelerate Your OMICs Data Analysis with the Fastest Solution on the Market
We address the most important hurdles in current omics data analysis, revolutionising the Life Sciences
Current Challenges of OMICs Analysis
Omics data, including DNA, RNA and protein data, is challenging to manage and analyse:All data resides in silo's and are hard to integrate.Each data set requires a multitude of analysis tools and workflows.All data, new and existing, are so large that processing it outruns computer power.
The heterogeneity of omics data is the common cause of these challenges.How can we use OMICs data more efficiently?Transversal OMICs language -HYFTsTM
The Unique BioStrand Solution
An integrative and scalable technology using a new, transversal language (HYFTsTM). HYFTsTM is capable of handling all of the complexity in biology.
Default integration of OMICs layers and associated metadata
Gathering multiple tools and tasks in a universal workflow
Scalable platform leveraging proven big data technology
Discover how BioStrand disrupts the OMICs analysis marketLearn more about our technology
BioStrand OMICs Analysis Solutions
Single User Tool: Retrieve & Relate
This is the ultimate search engine for multi-omics data for bioinformaticians and researchers. Retrieve & Relate (R&R) is a self-service omics data analysis platform making all omics data insightful and searchable. Our platform offers you a shortcut to new insights & knowledge: reveal what is already hidden in your data.The ultimate search engine for multi-omics data.Capable of performing cross database lookups, Retrieve & Relate is your go to sequence search tool.Surpassing state of art tools in the amount of information included, speed and accuracy. R&R enables you to find similar sequences across multiple databases in just seconds.Next to simultaneous multi database search, we also search across all omics layers. Learn more
Enterprises: Omics Data Analysis & Management Platform
Our Omics Management & Analysis tool empowers organisations to accelerate their genomics projects for convenience and cost-effectiveness. We provide a unified platform for enterprises to perform big data omics analytics on a large scale- and with lightning speed. Features include:Capability to solve the mismatch between omics data generation and analysis capacity.Universal, scalable framework to manage and analyse extremely heterogeneous omics data and making them real-time and actionable.Platform that functions as the ERP of omics, combining all omics data – public, proprietary and meta data – into a single application.The result is data that is fully harmonised in a unified framework. Learn more
One Integrated Workflow
Information on every organism of our planet is instantly searchable. Determine the scope of your analysis and zoom in-and-out on results and interpretation without borders.
A search engine for applying algorithmic principles for the quick retrieval of biological sequence data on all molecular layers enables analysis of big data, across multiple data sources, at high speed, with a high degree of high accuracy.
HYFT™ Information Network as a Hybrid Solution
HYFTs™ are signature sequences across species that serve as structural anchor points and carry a multitude of information layers. All of those patterns make up the HYFTs™ information network that can be linked to relevant real-world data such as clinical data, disease pathways, compound data…
A Revolutionary Approach to Structure and Function Prediction
Completely integrating sequence and 3D structure analysis will revolutionise protein structure and function prediction and boost developments in precision medicine.
Prof. Dirk Valkenborg from Hasselt University explains the benefits of working with BioStrand's technology.Learn more about our technology
April 14, 2022
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue
VICTORIA, BRITISH COLUMBIA (CANADA), April 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over..
The role of NGS in breast cancer diagnosis and treatment
Breast cancer is the most common cancer in women worldwide, accounting for 25% of all female cancers, and the most common cause of cancer death in..
Explained: how to plot the prediction quality metrics with AlphaFold2
In a previous blog post, we discussed the importance of AlphaFold2 (as well as other, deep-learning based methods) to accelerate the process of drug..
IPA MedTech Entrepreneurship Story at TU Delft
My name is Christophe Van Neste, Ph. D. and I am a bioinformatician and data scientist at IPA, supporting LENSai™ Complex Intelligence Technology...
BioStrand is a part of IPA
Let us explore how we can help you!
<<< Thank you for your visit >>>